Coronado Biosciences
As of the edition of 20 October 2026, Coronado Biosciences runs 8 drugs, 5 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 6 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 5 |
| Active | 2 |
| Stopped | 1 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Minocycline | none listed | 0 |
| Glycopyrronium | none listed | 10 |
| Copper histidine | Ends 2033 (exclusivity) | 0 |
| Crotamiton | none listed | 0 |
| Sulconazole | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Skin and connective tissue: 4 trials led
- Blood and lymph: 2 trials led
- Cancer: 2 trials led